Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Financial Results (May 5, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 5, 2025
Period End
May 5, 2025
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed May 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported first-quarter 2025 results for the period ended March 31, 2025, with total revenues of $572.6 milliona, up from $515.3 million a year earlier.

INGREZZA net product sales were $545.2 millionb, which the company states represents 8% growth compared with the first quarter of 2024, driven by record new patient starts and improved gross-to-net dynamics. CRENESSITY, in its initial launch, generated net product sales of $14.5 million and 413 total patient enrollment start forms. GAAP net income fell to $7.9 million, or $0.08 per diluted share, from $43.4 million, or $0.42 per diluted share.

Non-GAAP net income was $71.5 millionc, or $0.70 per diluted share, compared with $124.8 million, or $1.20 per diluted share. The decline reflects higher R&D and SG&A expense, including a $45 million development milestone in R&D tied to the start of the osavampator Phase 3 program, and a $31 million loss from changes in fair values of equity investments. The company reaffirmed its 2025 guidance, including INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D expense of $960 to $1,010 million, and GAAP SG&A expense of $1,110 to $1,130 million.

Management highlighted the initiation of two Phase 3 registrational programs, for osavampator in major depressive disorder and NBI-1117568 in schizophrenia, along with Phase 1 studies for NBI-921355 and NBI-1140675. Total cash, cash equivalents, and marketable securities were $1,758.8 milliond at March 31, 2025, versus $1,815.6 million at December 31, 2024. The company completed a $300 million accelerated share repurchase on February 5, 2025, and had repurchased $150 million under a second $500 million program, with $350 million remaining.

The filing also notes the appointment of Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025, and top-line data from the Phase 4 KINECT-PRO study of INGREZZA in tardive dyskinesia. Management described the combination of INGREZZA and CRENESSITY as a solid foundation for near- and long-term revenue growth.

Key Highlights

  1. Total revenues rose to $572.6 million from $515.3 million, with INGREZZA net product sales of $545.2 million (8% growth year over year) and CRENESSITY net product sales of $14.5 million in its launch quarter.
  2. GAAP net income declined to $7.9 million ($0.08 per diluted share) from $43.4 million ($0.42), while non-GAAP net income was $71.5 million ($0.70 per diluted share) versus $124.8 million ($1.20).
  3. GAAP R&D expense increased to $263.2 million from $159.4 million, including a $45 million development milestone primarily tied to the osavampator Phase 3 initiation; GAAP SG&A was $276.5 million versus $243.1 million.
  4. 2025 guidance was reaffirmed: INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D of $960 to $1,010 million, and GAAP SG&A of $1,110 to $1,130 million.
  5. Two Phase 3 registrational programs were initiated: osavampator for major depressive disorder and NBI-1117568 for schizophrenia, alongside Phase 1 studies of NBI-921355 and NBI-1140675.
  6. Capital returns continued: a $300 million accelerated share repurchase was completed on February 5, 2025, and $150 million of a $500 million second program had been repurchased by March 31, 2025, leaving $350 million authorized.
  7. Cash, cash equivalents, and marketable securities totaled $1,758.8 million at March 31, 2025, down from $1,815.6 million at December 31, 2024.

Frequently Asked Questions

  1. How did INGREZZA perform in the first quarter of 2025?

    INGREZZA net product sales were $545.2 million, compared with $506.0 million in the first quarter of 2024. The company states this represents 8% growth, driven by record new patient starts and improved gross-to-net dynamics, and expanded formulary access now covers two-thirds of tardive dyskinesia and Huntington’s disease Medicare beneficiaries.

  2. How is the CRENESSITY launch progressing?

    CRENESSITY generated first-quarter 2025 net product sales of $14.5 million and 413 total patient enrollment start forms. The company reports approximately 70% reimbursement coverage for dispensed scripts and describes the initial patient demand as strong.

  3. Why did GAAP earnings decline compared with the prior year?

    GAAP net income was $7.9 million ($0.08 per diluted share) versus $43.4 million ($0.42) a year earlier. The filing attributes the change to higher operating expenses supporting the R&D portfolio, CRENESSITY launch costs, and the INGREZZA sales force expansion, plus a $45 million development milestone in R&D and a $31 million loss from changes in fair values of equity investments.

  4. Did the company change its 2025 financial guidance?

    No. Neurocrine reaffirmed its 2025 guidance, including INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D expense of $960 to $1,010 million, and GAAP SG&A expense of $1,110 to $1,130 million. R&D guidance includes $60 million of expense for development milestones tied to collaborations with Takeda and Nxera.

  5. What are the company's capital allocation actions?

    The company completed a $300 million accelerated share repurchase on February 5, 2025. Under a second program authorized February 21, 2025 for up to $500 million, it had repurchased $150 million as of March 31, 2025, with $350 million remaining. Cash, cash equivalents, and marketable securities were $1,758.8 million at quarter end.